Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer
- PMID: 2783889
- PMCID: PMC11038005
- DOI: 10.1007/BF00199115
Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer
Abstract
Characterization of T-lymphocyte subpopulations adjacent to and infiltrating the primary tumor of breast cancer was carried out using a direct immunofluorescence procedure with the antibodies anti-(Leu-2a) for suppressor/cytotoxic (CD8+) and anti-(Leu-3a) for helper/inducer (CD4+) T-lymphocytes. Fifty-six primary malignant tumors with lymphoid infiltration were studied. The majority (58.9%) were infiltrating duct carcinoma. There were metastases to axillary lymph nodes in 6.67% of the patients. Massive lymphoid infiltration (greater than 40 lymphocytes per x 400 microscopic field) was found in 19.6% of the tumors and moderate infiltration (20-40 lymphocytes per field) in 51.8%. In all the tumors studied there was a reversed CD4+/CD8+ ratio as compared to that found in normal peripheral blood. In 66.1% the CD4+/CD8+ ratio (helper/suppressor) was less than 1.0. The reversed ratio was due to a significant decrease in the number of helper cells (P less than 0.0005). The most significant drop was in the stroma area (P less than 0.0001) as well as in the tumor tissue (P = 0.001). Of particular interest was the significant positive correlation between the age of the patients and an increased number of CD4+lymphocytes in the stroma (P = 0.02). Significant negative correlations were found between a reduced number of CD4+ lymphocytes or CD4+/CD8+ ratio and several histological parameters: tumor diameter, pleomorphism, nucleus/cytoplasm ratio. There was also a significant positive correlation between the total number of CD8+ lymphocytes infiltrating the tumor tissue and the number of axillary lymph nodes with metastatic disease (P = 0.03). It is suggested that the reversed ratio of CD4+/CD8+ lymphocytes may significantly affect the host/tumor immune surveillance.
Similar articles
-
Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement.Clinics (Sao Paulo). 2006 Jun;61(3):203-8. doi: 10.1590/s1807-59322006000300004. Epub 2006 Jun 30. Clinics (Sao Paulo). 2006. PMID: 16832552
-
Identification and importance of lymphocyte subpopulations in the regional lymph nodes of breast cancer patients.Can J Surg. 1989 Jan;32(1):23-6. Can J Surg. 1989. PMID: 2463069
-
Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.Cancer. 1994 Aug 15;74(4):1275-82. doi: 10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q. Cancer. 1994. PMID: 7914469
-
T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer.Head Neck. 1989 Jul-Aug;11(4):331-6. doi: 10.1002/hed.2880110408. Head Neck. 1989. PMID: 2502505
-
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer.PLoS Med. 2005 Sep;2(9):e284. doi: 10.1371/journal.pmed.0020284. Epub 2005 Sep 6. PLoS Med. 2005. PMID: 16124834 Free PMC article.
Cited by
-
Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.Cancer Immunol Immunother. 1990;32(3):154-60. doi: 10.1007/BF01771450. Cancer Immunol Immunother. 1990. PMID: 2126987 Free PMC article.
-
Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.Cancer Immunol Immunother. 1992;35(5):297-301. doi: 10.1007/BF01741141. Cancer Immunol Immunother. 1992. PMID: 1394333 Free PMC article.
-
Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.Breast Cancer Res Treat. 1992;24(1):17-26. doi: 10.1007/BF01832354. Breast Cancer Res Treat. 1992. PMID: 1463868
-
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.BMC Cancer. 2008 Jun 21;8:176. doi: 10.1186/1471-2407-8-176. BMC Cancer. 2008. PMID: 18570671 Free PMC article.
-
Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.Cancer Immunol Immunother. 1994 Jul;39(1):15-21. doi: 10.1007/BF01517175. Cancer Immunol Immunother. 1994. PMID: 8044822 Free PMC article. Review. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials